spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Protagen Protein Services (PPS) reaches new level in characterizing HCP protein impurities

Protagen Protein Services


In response to current regulatory guidance a Mass Spectrometry (MS) based Host Cell Protein (HCP) detection approach with faster, more accurate and wider-ranging detection is essential. In order to meet the newly prevailing demands Protagen Protein Services (PPS) recently invested in more far-reaching MS capabilities: The new high-performing mass spectrometer ThermoFisher Q Exactive™ HF-X started operational service last month and brings PPS to the next level of reproducible, accurate and sensitive analyses of majorly complex samples for different aspects of translational research and biopharma applications.

Heilbronn/Dortmund January 2019: The study of biomolecules for potential use as therapeutic agents requires the analysis of highly complex samples. This includes full characterization of complex biotherapeutics as well as comprehensive proteome profiling and quantitation. Developers of biosimilars and new biological entities demand in-depth analysis, high-end data quality and analytical precision without compromising on robustness or speed.



The new high-performing MS device not only allows to detect a higher number of proteins and peptides but also delivers much higher accuracy than previous models. The extended capabilities offer an up to eight times improved signal to noise ratio for intact, native monoclonal antibody mass determination. A higher scan rate simultaneously enables the detection of multiple attributes (MAM) for peptide based analysis like PTM characterization or glycoprofiling as well as it reaches a new level in characterizing protein impurities such as HCPs.



Residual host cell proteins (HCPs) are ppm-level contaminants in biotherapeutics that may elicit an unpredictable immune response in patients and need to be monitored meticulously. The new high-performing instrument gives access to a more accurate approach that detects a wider population of HCPs than traditional ELISA technologies. “Due to our long-term experience, our intuitive specialized bioinformatics and to our newly acquired high-end MS technologies we are now able to offer advanced MS as a technique for the comprehensive analysis of HCPs in our clients’ products”, says Dr. Heiner Falkenberg, MS Team Leader at PPS. In DSP characterization the detectable HCPs in one mAb product were increased by a factor of about 4 (49 versus 12 HCPs) by using the newest technology. “The perspective that high-end MS technologies offer”, adds Falkenberg, “has been inspiring regulatory groups worldwide, who by now often recommend MS as an orthogonal approach to HCP-ELISA.”

In contrast to HCP-ELISA, which relies on the presence of polyclonal antibodies for positive HCP detection, the amplified qualities of high-performing mass spectrometers such as the ThermoFisher Q Exactive™ HF-X offer the advantage of detecting HCPs in a de novo manner, without specialized polyclonal antibody reagents or product-/process-specific method development. At PPS, we apply our profound MS expertise within a clearly defined staged approach including

• qualitative analysis aiming at the identification of low abundant HCPs in the drug substance,
• quantitation of low abundant HCPs relative to purification-process samples, and
• absolute quantitation of HCPs against heavy labeled marker peptides.
“We remain committed to positioning ourselves at the forefront, constantly looking for innovations and thus bringing the best technical and analytical service to our clients”, emphasizes Dr. Heiner Falkenberg. “We are improving HCP assessments significantly by means of the more decisive analytical technique of MS and we look forward to serving our clients with our extended options in HCP detection.”

Besides the new Mass Spectrometry (MS) based HCP detection approach method it is outmost important also to analyze the protein research object with other indicating methods. Learn more from our broad analytical spectrum at www.protagenproteinservices.com.

About Protagen Protein Services GmbH (PPS):

Protagen Protein Services (PPS) is a world leading CRO and recognized expert in mass spectrometry methods for analytical services in protein science. Over 20 years of market experience and the comprehensive spectrum of validated analytical methods ensure the highest quality for customers in the pharmaceutical, biotech and life science industry. PPS supports Biosimilar developers with a broad range of analytical methods and consulting in achieving and demonstrating Biosimilarity. For developing new biological entities (NBEs) PPS supports customer approaches by all-in-one-hand service with including full analytical support, complete documentation and outstanding project management to gain market success.

Contact:
Tobias Timtner
Marketing Manager
Tel.: +49 7131 74504-0
Fax: +49 7131 74 504-299
Protagen Protein Services GmbH
Inselwiesenstraße 10
74076 Heilbronn, Germany
phone +49 231 9742 61 00
email contact@protagenproteinservices.com
web www.protagenproteinservices.com
email Protagen Protein Services (GmbH), Inselwiesenstraße 10, D-74076 Heilbronn
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Are you keeping up to date with changes to pharmaceutical laws and guidance?

The legal and regulatory environment affecting the pharmaceutical industry is in a period of unprecedented change. Are you keeping up with all these changes?
More info >>


White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research

BioFortis

Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>

Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement